Hydromorphon Al

Hydromorphone, the active ingredient in Hydromorphon Al, is an opioid analgesic presented as an oral dosage form for oral use. It is indicated for the management of severe acute pain, post‑operative pain, and cancer‑related pain in adult patients requiring strong analgesia.

GNH USA supplies Hydromorphon Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for regulated medicines across multiple regions. Ensuring timely delivery and regulatory compliance.

Hydromorphone, a potent μ‑opioid receptor agonist, is employed in clinical practice to manage severe pain states that require strong opioid therapy.

- Severe acute pain: rapid relief of intense pain episodes such as trauma, burns, or acute injury. - Post‑operative pain: effective control of pain following major surgical procedures. - Cancer‑related pain: provides potent analgesia for malignant disease‑associated pain that is unresponsive to weaker analgesics.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Constipation: reduced bowel motility leading to hard stools. - Drowsiness: increased sleepiness or reduced alertness. - Dizziness: sensation of light‑headedness or unsteadiness. - Dry mouth: reduced salivation causing throat discomfort. - Sweating: excessive perspiration unrelated to temperature.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing faintness. - Seizures: rare occurrence of convulsive episodes. - Adrenal insufficiency: impaired cortisol production. - Anaphylaxis: acute allergic reaction with airway compromise. - Dependence or addiction: development of physical or psychological reliance on the drug.

Hydromorphone should be prescribed only after a thorough assessment of pain severity and patient history.

- Assess pain severity: confirm that opioid therapy is clinically justified. - Monitor respiratory function: observe for signs of respiratory depression, especially after dose initiation. - Evaluate renal and hepatic function: adjust dosing in patients with organ impairment. - Avoid use in patients with known hypersensitivity to hydromorphone or other opioids. - Use the lowest effective dose: titrate to pain control while minimizing adverse effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Hydromorphone may interact with other medications, altering its safety or effectiveness.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines, barbiturates): increased risk of profound sedation and respiratory depression. - Monoamine oxidase inhibitors (MAOIs): can precipitate severe hypertension or serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise hydromorphone plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic effect. - Antihistamines and anticholinergics: can enhance anticholinergic side effects such as dry mouth and constipation.